Company · Healthcare
Biotech developing an experimental oral treatment for type 1 diabetes
Melbourne, VIC
Every investor coverage indicates participated in a round ImmunoBiota Therapeutics raised.
Companies ImmunoBiota Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Eliana Marino | CEO · Founder | Business News Australia, Startup Daily |
Stories naming ImmunoBiota Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech ImmunoBiota courts investors for its still-open seed round around an oral Type 1 diabetes therapy; its recent Diabetes Australia award is recorded, while the flagged Series A and listing remain plans.
Melbourne biotech ImmunoBiota Therapeutics, a Monash University spinout, is developing an oral type 1 diabetes treatment and seeking seed funding for paediatric trials; its founder won a Diabetes Australia innovation prize.